You are here

Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia

Last updated on March 14, 2019

FOR MORE INFORMATION
Study Location
Tucson, Arizona, United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Postherpetic Neuralgia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Diagnosis of PHN made by primary treating physician and is experiencing pain for at
least 3 months after the healing of a herpes zoster rash.

2. Subject is in general good health.

3. Females must be non-pregnant, non-lactating, and practicing an acceptable method of
birth control or be surgically sterile or post-menopausal. Double barrier methods and
abstinence are the only acceptable birth control methods for this study.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Subject has a current acute disease or unstable chronic disease other than post
herpetic neuralgia.

2. Subject has a clinically important history of a medical disorder (particularly
cardiovascular, neurological [e.g., diabetic neuropathy], respiratory, or
hepato-biliary systems [e.g., Gilbert Syndrome]) that would confound and/or interfere
with the safety and efficacy evaluations defined in the protocol.

3. Subject is being treated for a medical condition that affects cardiac conduction.

4. Subject's plasma alanine aminotransferase (ALT) aspartate aminotransferase (AST),
total bilirubin, and alkaline phosphatase (AP) values are not within the normal
reference ranges.

5. Subject has a history of asthma requiring management for reactive airway disease in
the last year.

6. Subject uses and is unwilling/unable to discontinue use of (A) Lyrica® (pregabalin),
Cymbalta® (duloxetine), Neurontin® (gabapentin), topical lidocaine, topical capsaicin,
or other medication specifically indicated (i.e., labeled) for the treatment of
neuropathic pain, or (B) anticonvulsant medications to control post herpetic
neuralgia.

7. Subject currently requires anticonvulsant medications to control seizures.

NCT00809679
Pfizer
Terminated
Analgesic Efficacy and Safety Study of T-62 in Subjects With Postherpetic Neuralgia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now